Illumina, Inc. (NASDAQ:ILMN) EVP Marc Stapley sold 2,000 shares of the business’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $219.88, for a total transaction of $439,760.00. Following the completion of the transaction, the executive vice president now owns 29,198 shares in the company, valued at approximately $6,420,056.24. The sale was disclosed in a legal filing with the SEC, which is available through this link.
Marc Stapley also recently made the following trade(s):
- On Wednesday, November 15th, Marc Stapley sold 2,000 shares of Illumina stock. The shares were sold at an average price of $205.48, for a total transaction of $410,960.00.
- On Thursday, October 26th, Marc Stapley sold 2,000 shares of Illumina stock. The stock was sold at an average price of $206.88, for a total transaction of $413,760.00.
Shares of Illumina, Inc. (NASDAQ:ILMN) traded up $2.92 during trading hours on Wednesday, hitting $213.98. 654,770 shares of the company traded hands, compared to its average volume of 957,041. The company has a current ratio of 4.22, a quick ratio of 3.73 and a debt-to-equity ratio of 0.41. The stock has a market cap of $30,920.00, a P/E ratio of 62.41, a PEG ratio of 3.53 and a beta of 0.79. Illumina, Inc. has a fifty-two week low of $119.37 and a fifty-two week high of $230.72.
Several research analysts have commented on ILMN shares. Barclays upped their target price on shares of Illumina from $150.00 to $185.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 25th. Zacks Investment Research upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $229.00 target price for the company in a research report on Friday, October 27th. Canaccord Genuity restated a “buy” rating and issued a $230.00 target price (up previously from $215.00) on shares of Illumina in a research report on Thursday, October 12th. Piper Jaffray Companies restated an “overweight” rating and issued a $226.00 target price (up previously from $202.00) on shares of Illumina in a research report on Monday, October 9th. Finally, Janney Montgomery Scott upgraded shares of Illumina from a “sell” rating to a “neutral” rating in a research report on Monday, October 23rd. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and fourteen have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $201.98.
Large investors have recently modified their holdings of the stock. Winslow Capital Management LLC acquired a new position in Illumina in the 2nd quarter valued at approximately $211,584,000. HPM Partners LLC increased its stake in Illumina by 29,103.8% in the 2nd quarter. HPM Partners LLC now owns 751,999 shares of the life sciences company’s stock valued at $107,724,000 after buying an additional 749,424 shares during the period. Fred Alger Management Inc. increased its stake in Illumina by 611.9% in the 2nd quarter. Fred Alger Management Inc. now owns 637,597 shares of the life sciences company’s stock valued at $110,636,000 after buying an additional 548,030 shares during the period. TIAA CREF Investment Management LLC increased its stake in Illumina by 55.6% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 1,475,669 shares of the life sciences company’s stock valued at $256,058,000 after buying an additional 527,548 shares during the period. Finally, Capital World Investors increased its stake in Illumina by 23.8% in the 2nd quarter. Capital World Investors now owns 2,135,000 shares of the life sciences company’s stock valued at $370,465,000 after buying an additional 410,000 shares during the period. Institutional investors and hedge funds own 91.75% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Marc Stapley Sells 2,000 Shares of Illumina, Inc. (ILMN) Stock” was published by Ticker Report and is the property of of Ticker Report. If you are accessing this article on another website, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this article can be accessed at https://www.tickerreport.com/banking-finance/3078360/marc-stapley-sells-2000-shares-of-illumina-inc-ilmn-stock.html.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.